Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03086343




Registration number
NCT03086343
Ethics application status
Date submitted
20/03/2017
Date registered
22/03/2017
Date last updated
18/07/2024

Titles & IDs
Public title
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
Scientific title
A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Secondary ID [1] 0 0
2016-000933-37
Secondary ID [2] 0 0
M15-925
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis (RA) 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Abatacept
Treatment: Drugs - Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
Treatment: Drugs - Upadacitinib
Treatment: Drugs - Placebo for upadacitinib

Active comparator: Primary Cohort: Abatacept/Upadacitinib 15 mg QD - Period 1: 500 mg (for body weight \<60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight \>100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 15 mg QD for 192 weeks.

Experimental: Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD - Period 1: One 15 mg upadacitinib oral tablet QD for 24 weeks. Period 2: open label upadacitinib 15 mg QD for 192 weeks.

Experimental: 30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD - Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.

Active comparator: 30 mg Cohort: Abatacept/Upadacitinib 30 mg QD - Period 1: 500 mg (for body weight \<60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight \>100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.


Treatment: Drugs: Abatacept
IV infusion

Treatment: Drugs: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
IV infusion

Treatment: Drugs: Upadacitinib
15 mg extended release tablet

Treatment: Drugs: Placebo for upadacitinib
Film-coated tablet
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority)
Timepoint [1] 0 0
Baseline and Week 12
Secondary outcome [1] 0 0
Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority)
Timepoint [1] 0 0
Baseline and Week 12
Secondary outcome [2] 0 0
Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority)
Timepoint [2] 0 0
At Week 12

Eligibility
Key inclusion criteria
Main

* Diagnosis of rheumatoid arthritis (RA) for = 3 months who also fulfill the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA
* Participants have been treated for = 3 months prior to the screening visit with = 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration and have never received abatacept prior to the first dose of study drug
* Participants have been receiving csDMARD therapy = 3 months and on a stable dose for = 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide. A combination of up to two background csDMARDs is allowed except the combination of MTX and leflunomide
* Meets the following criteria: = 6 swollen joints (based on 66 joint counts) and = 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits and high-sensitivity C-reactive protein (hsCRP) = 3 mg/L at Screening

Main
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib and filgotinib)
* Prior exposure to abatacept
* History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted
* Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase > 2 × upper limit of normal (ULN); serum alanine transaminase > 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula < 40 mL/minute/1.73 meter (m)^2; total white blood cell count < 2,500/ µL; absolute neutrophil count < 1,500/µL; platelet count < 100,000/µL; absolute lymphocyte count < 800/µL; and hemoglobin < 10 g/dL

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/05/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
6/06/2023
Sample size
Target
Accrual to date
Final
657
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Rheumatology Research Unit /ID# 159174 - Maroochydore
Recruitment hospital [2] 0 0
The Queen Elizabeth Hospital /ID# 159175 - Woodville
Recruitment hospital [3] 0 0
Western Health Footscray Hospi /ID# 157968 - Footscray
Recruitment postcode(s) [1] 0 0
4558 - Maroochydore
Recruitment postcode(s) [2] 0 0
5011 - Woodville
Recruitment postcode(s) [3] 0 0
3011 - Footscray
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Caba
Country [25] 0 0
Argentina
State/province [25] 0 0
Cordoba
Country [26] 0 0
Argentina
State/province [26] 0 0
Ramos Mejía
Country [27] 0 0
Argentina
State/province [27] 0 0
Rosario, Santa FE
Country [28] 0 0
Belgium
State/province [28] 0 0
Namur
Country [29] 0 0
Brazil
State/province [29] 0 0
Espirito Santo
Country [30] 0 0
Brazil
State/province [30] 0 0
Minas Gerais
Country [31] 0 0
Brazil
State/province [31] 0 0
Parana
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio Grande Do Sul
Country [33] 0 0
Brazil
State/province [33] 0 0
Sao Paulo
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Plovdiv
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Sofia
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha 2
Country [39] 0 0
Czechia
State/province [39] 0 0
Uherské Hradište
Country [40] 0 0
Germany
State/province [40] 0 0
Nordrhein-Westfalen
Country [41] 0 0
Germany
State/province [41] 0 0
Berlin
Country [42] 0 0
Germany
State/province [42] 0 0
Hamburg
Country [43] 0 0
Germany
State/province [43] 0 0
Planegg
Country [44] 0 0
Greece
State/province [44] 0 0
Heraklion
Country [45] 0 0
Hungary
State/province [45] 0 0
Budapest
Country [46] 0 0
Hungary
State/province [46] 0 0
Debrecen
Country [47] 0 0
Hungary
State/province [47] 0 0
Eger
Country [48] 0 0
Hungary
State/province [48] 0 0
Szolnok
Country [49] 0 0
Ireland
State/province [49] 0 0
Manorhamilton
Country [50] 0 0
Israel
State/province [50] 0 0
Ashkelon
Country [51] 0 0
Israel
State/province [51] 0 0
Haifa
Country [52] 0 0
Israel
State/province [52] 0 0
Kfar Saba
Country [53] 0 0
Israel
State/province [53] 0 0
Ramat Gan
Country [54] 0 0
Italy
State/province [54] 0 0
Marche
Country [55] 0 0
Italy
State/province [55] 0 0
Milano
Country [56] 0 0
Italy
State/province [56] 0 0
Piemonte
Country [57] 0 0
Italy
State/province [57] 0 0
Roma
Country [58] 0 0
Italy
State/province [58] 0 0
Catania
Country [59] 0 0
Italy
State/province [59] 0 0
Milan
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul Teugbyeolsi
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Seoul
Country [62] 0 0
Latvia
State/province [62] 0 0
Liepaja
Country [63] 0 0
Latvia
State/province [63] 0 0
Riga
Country [64] 0 0
Mexico
State/province [64] 0 0
Ciudad De Mexico
Country [65] 0 0
Mexico
State/province [65] 0 0
Guanajuato
Country [66] 0 0
Mexico
State/province [66] 0 0
Jalisco
Country [67] 0 0
Mexico
State/province [67] 0 0
Mexico City
Country [68] 0 0
Netherlands
State/province [68] 0 0
Fryslan
Country [69] 0 0
Netherlands
State/province [69] 0 0
Amsterdam
Country [70] 0 0
Netherlands
State/province [70] 0 0
Haarlem
Country [71] 0 0
Netherlands
State/province [71] 0 0
Leeuwarden
Country [72] 0 0
New Zealand
State/province [72] 0 0
Timaru
Country [73] 0 0
New Zealand
State/province [73] 0 0
Wellington
Country [74] 0 0
Poland
State/province [74] 0 0
Lodzkie
Country [75] 0 0
Poland
State/province [75] 0 0
Malopolskie
Country [76] 0 0
Poland
State/province [76] 0 0
Mazowieckie
Country [77] 0 0
Poland
State/province [77] 0 0
Podlaskie
Country [78] 0 0
Poland
State/province [78] 0 0
Pomorskie
Country [79] 0 0
Poland
State/province [79] 0 0
Wielkopolskie
Country [80] 0 0
Poland
State/province [80] 0 0
Lodz
Country [81] 0 0
Portugal
State/province [81] 0 0
Lisboa
Country [82] 0 0
Portugal
State/province [82] 0 0
Setubal
Country [83] 0 0
Portugal
State/province [83] 0 0
Viana Do Castelo
Country [84] 0 0
Portugal
State/province [84] 0 0
Viseu
Country [85] 0 0
Puerto Rico
State/province [85] 0 0
Carolina
Country [86] 0 0
Puerto Rico
State/province [86] 0 0
San Juan
Country [87] 0 0
Romania
State/province [87] 0 0
Bucuresti
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Moskva
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Novosibirskaya Oblast
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Udmurtskaya Respublika
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Moscow
Country [92] 0 0
Russian Federation
State/province [92] 0 0
St. Petersburg
Country [93] 0 0
Slovakia
State/province [93] 0 0
Banska Bystrica
Country [94] 0 0
Slovakia
State/province [94] 0 0
Bratislava
Country [95] 0 0
Slovakia
State/province [95] 0 0
Pieštany
Country [96] 0 0
Spain
State/province [96] 0 0
Cordoba
Country [97] 0 0
Spain
State/province [97] 0 0
Elche
Country [98] 0 0
Spain
State/province [98] 0 0
Madrid
Country [99] 0 0
Spain
State/province [99] 0 0
Sabadell, Barcelona
Country [100] 0 0
Spain
State/province [100] 0 0
Santiago de Compostela
Country [101] 0 0
Spain
State/province [101] 0 0
Sevilla
Country [102] 0 0
Sweden
State/province [102] 0 0
Skane Lan
Country [103] 0 0
Sweden
State/province [103] 0 0
Stockholms Lan
Country [104] 0 0
Sweden
State/province [104] 0 0
Goteborg
Country [105] 0 0
Sweden
State/province [105] 0 0
Vasteras
Country [106] 0 0
Switzerland
State/province [106] 0 0
Geneve
Country [107] 0 0
Switzerland
State/province [107] 0 0
Sankt Gallen
Country [108] 0 0
Switzerland
State/province [108] 0 0
Basel
Country [109] 0 0
Switzerland
State/province [109] 0 0
Fribourg
Country [110] 0 0
Turkey
State/province [110] 0 0
Ankara
Country [111] 0 0
Turkey
State/province [111] 0 0
Antalya
Country [112] 0 0
Turkey
State/province [112] 0 0
Istanbul
Country [113] 0 0
United Kingdom
State/province [113] 0 0
London, City Of
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Dundee
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Londonderry
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Preston
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in biologic disease-modifying antirheumatic drug (bDMARD)-inadequate response or bDMARD-intolerant participants with moderately to severely active RA. The study objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in participants with RA who had completed Period 1.
Trial website
https://clinicaltrials.gov/study/NCT03086343
Trial related presentations / publications
Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, Zhang Y, Martin N, Xavier RM. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020 Oct 15;383(16):1511-1521. doi: 10.1056/NEJMoa2008250.
Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Res Ther. 2022 Jun 24;24(1):155. doi: 10.1186/s13075-022-02813-x. Erratum In: Arthritis Res Ther. 2022 Nov 3;24(1):248. doi: 10.1186/s13075-022-02940-5.
Public notes

Contacts
Principal investigator
Name 0 0
AbbVie Inc.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03086343